Background: Although the pathogenesis of toluene diisocyanate (TDI)-induced occupational asthma (TDI-OA) is incompletely understood, several studies have suggested immunologic mechanisms, including specific IgE responses. A few studies have suggested human leukocyte antigen (HLA) associations with TDI-induced asthma in Western countries, but this is the first investigation of associations between HLA class I and II alleles and TDI-induced asthma patients in Asia, using high-resolution analysis. Methods: Patients with TDI-OA (n = 84), asymptomatic exposed controls (AECs, n = 47) and unexposed normal controls (NCs, n = 127) were enrolled. HLA class I and II genotyping was performed by the direct DNA sequencing analysis. Specific serum IgE antibodies to the vapor type TDI-albumin conjugate were measured by ELISA. Results: There was no significant association between the allele frequencies and the phenotype of TDI-OA. However, the frequency of the HLA DRB1*1501-DQB1*0602-DPB1*0501 haplotype was significantly higher in TDI-OA patients (19%) than in AEC (2.1%, p = 0.007, OR 4.429, CI 1.497–13.103) or NC (3.1%, p < 0.001, OR 7.235, CI 2.236–22.510) subjects, with statistical significance persisting after correction for multiple comparisons. DQB1*0402 was significantly associated with the presence of specific IgE to TDI-albumin conjugates in serum (p = 0.006, OR 4.552, CI 1.540–13.449). This p value remained significant after correction for multiple comparison. Conclusion: The HLA DRB1*1501-DQB1*0602-DPB1*0501 haplotype may be a genetic marker for the development of TDI-induced asthma in Koreans. Several HLA alleles that enhance specific IgE sensitization in exposed subjects are indicated.

Keywords:
Toluene diisocyanate, Asthma, Human leukocyte antigen class, Immunoglobulin E
1.
Wisnewski AV, Redlich CA, Mapp CE, Bernstein DI: Polyisocyanates and their prepolymers; in Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI (eds): Asthma in the Workplace, ed 3. New York, Tayor & Francis Group, 2006, pp 481–504.
2.
Mapp CE: Agents, old and new, causing occupational asthma. Occup Environ Med 2001;58:354–360.
3.
Kim YY, Cho SH, Yoon HJ, Min KU, Back DM, Jung KC: Isocyanate-induced occupational asthma in Korea. Korean J Med (Korean) 1994;47:439–453.
4.
Park HS, Park JN, Kim JW, Kim SK: Clinical and immunological evaluation of isocyanate-exposed workers. J Korean Med Sci 1992;7:122–127.
5.
Baur X: Occupational asthma due to isocyanates. Lung 1996;174:23–30.
6.
Wisnewski AV, Redlich CA: Recent developments in diisocyanate asthma. Curr Opin Allergy Clin Immunol 2001;1:169–175.
7.
Park HS, Cho SH, Hong CS, Kim YY: Isocyanate-induced occupational asthma in far-east Asia: pathogenesis to prognosis. Clin Exp Allergy 2002;32:198–204.
8.
Liu Q, Wisnewski AV: Recent developments in diisocyanate asthma. Ann Allergy Asthma Immunol 2003;90(suppl 2):35–41.
9.
Wisnewski AV: Developments in laboratory diagnostics for isocyanate asthma. Curr Opin Allergy Clin Immunol 2007;7:138–145.
10.
Cartier A, Grammer L, Malo JL, Lagier F, Ghezzo H, Harris K, Patterson R: Specific serum antibodies against isocyanates: association with occupational asthma. J Allergy Clin Immunol 1989;84:507–514.
11.
Park HS, Lee SK, Kim HY, Nahm DH, Kim SS: Specific immunoglobulin E and immunoglobulin G antibodies to toluene diisocyanate-human serum albumin conjugate: useful markers for predicting long-term prognosis in toluene diisocyanate-induced asthma. Clin Exp Allergy 2002;32:551–555.
12.
Bentley AM, Maestrelli P, Saetta M, Fabbri LM, Robinson DS, Bradley BL, Jeffery PK, Durham SR, Kay AB: Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992;89:821–829.
13.
Maestrelli P, Occari P, Turato G, Papiris SA, Di Stefano A, Mapp CE, Milani GF, Fabbri LM, Saetta M: Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy 1997;27:1292–1298.
14.
Wisnewski AV, Srivastava R, Herick C, Xu L, Lemus R, Cain H, Magoski NM, Karol MH, Bottomly K, Redlich CA: Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo. Am J Respir Crit Care Med 2000;162:2330–2336.
15.
Choi JH, Nahm DH, Kim SH, Kim YS, Suh CH, Park HS, Ahn SW: Increased levels of IgG to cytokeratin 19 in sera of patients with toluene diisocyanate-induced asthma. Ann Allergy Asthma Immunol 2004;93:293–298.
16.
Acton RT: The major histocompatibility complex; in Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HWJ (eds): Clinical Immunology, ed 2. London, Mosby, 2001, pp 6.1–6.13.
17.
Bignon JS, Aron Y, Ju LY, Kopferschmitt MC, Garnier R, Mapp C, Fabbri LM, Pauli G, Lockhart A, Charron D, Swierczewski E: HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med 1994;149:71–75.
18.
Balboni A, Baricordi OR, Fabbri LM, Gandini E, Ciaccia A, Mapp CE: Association between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic acid at position 57. Eur Respir J 1996;9:207–210.
19.
Mapp CE, Beghe B, Balboni A, Zamorani G, Padoan M, Jovine L, Baricordi OR, Fabbri LM: Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma. Clin Exp Allergy 2000;30:651–656.
20.
Rihs HP, Barbalho-Krolls T, Huber H, Baur X: No evidence for the influence of HLA class II in alleles in isocyanate-induced asthma. Am J Ind Med 1997;32:522–527.
21.
Kim SH, Oh HB, Lee KW, Shin ES, Kim CW, Hong CS, Nahm DH, Park HS: HLA DRB1*15-DPB1*05 haplotype: a susceptible gene marker for isocyanate-induced occupational asthma? Allergy 2006;61:891–894.
22.
Park HS, Kim HY, Nahm DH, Son JW, Kim YY: Specific IgG, but not specific IgE, antibodies to toluene diisocyanate-human serum albumin conjugate are associated with toluene diisocyanate bronchoprovocation test results. J Allergy Clin Immunol 1999;104:847–851.
23.
Ye YM, Kim CW, Kim HR, Kim HM, Suh CH, Nahm DH, Park HS, Redlich CA, Wisnewski AV: Biophysical determinants of toluene diisocyanate antigenecity associated with exposure and asthma. J Allergy Clin Immunol 2006;118:885–891.
24.
Wisnewski AV, Stowe MH, Cartier A, Liu Q, Liu J, Chen L, Redlich CA: Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol 2004;113:1178–1184.
25.
Blasczyk R: Sequence-based typing for HLA-DRB1 and DRB3/4/5 separating alleles; in Tilanus MGJ, Hansen JA, Hurley CK (eds): IHWG Technical Manual. Seattle, International Histocompatibility Working Group, 2000, TM10C 1–10.
26.
Schneider S, Rosseli D, Excoffier L: Arlequin 2000: a software for population genetics data analysis. Genetics and Biometry Laboratory, University of Geneva, 2000.
27.
Bernstein JA, Munson J, Lummus ZL, Balakrishnan K, Leikauf G: T-cell receptor V beta gene segment expression in diisocyanate-induced occupational asthma. J Allergy Clin Immunol 1997;99:245–250.
28.
Maestrelli P, Del Prete GF, De Carli M, D’Elios MM, Saetta M, Di Stefano A, Mapp CE, Romagnani S, Fabbri LM: CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994;20:376–381.
29.
Beghe B, Padoan M, Moss CT, Barton SJ, Holloway JW, Holgate ST, Howell WM, Mapp CE: Lack of association of HLA class I genes and TNF alpha-308 polymorphism in toluene diisocyanate-induced asthma. Allergy 2004;59:61–64.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.